The prognostic effect of immunohistochemical staining rates in patients with non-muscle-invasive bladder cancer

Basit Öğe Kaydı
dc.contributor.authorDemirci, Aykut
dc.contributor.authorOrdu, Melike
dc.date.accessioned2023-10-02T06:24:27Z
dc.date.available2023-10-02T06:24:27Z
dc.date.issued2023
dc.departmentTıp Fakültesi
dc.description.abstractContext: Despite the follow-up protocols developed in non-muscle-invasive bladder cancer patients, progression and recurrence could not be prevented. Aims: We aimed to investigate whether proteins such as OCT-4, CD47, p53, Ki-67, and Survivin, which increase in bladder cancer cells, can be used as prognostic markers for patients with non-muscle-invasive bladder cancer. Settings and Design: The study included a total of 89 patients with newly diagnosed non-muscle-invasive bladder cancer between January 2015 and December 2020. Materials and Methods: Levels of OCT-4, CD47, p53, Kİ-67, and Survivin proteins in cancer cells were determined with a semi-quantitative immunohistochemical experiment. Pathological data and survival rates were compared according to the staining rates. Statistical Analysis Used: Data obtained in the study were analyzed statistically with SPSS 22.0 (SPSS, Chicago, IL, USA). Results: The mean age of the patients was 64.25 ± 9.91 years, and the median follow-up period was 55 months. Recurrence rate was determined to be 36% (n = 32), and the rate of progression at 40.4% (n = 36). The staining rates were stronger for each marker in the progression group and advanced-stage tumors (p < 0.001). The findings of the multivariate analysis carried out as part of the study showed that older age and higher tumor stage were independent risk factors for recurrence-free survival (HR = 1.048 and 7.074, respectively; P = 0.02). Also, higher tumor stages, diameters, and grades were associated with reduced progression-free survival (HR = 0.105, 0.395, 0.225, respectively; P < 0.05). Conclusions: Although immunohistochemical staining rates are promising, it is more appropriate to use tumor characteristics when assessing survival rate in patients with non-muscle-invasive bladder cancer.
dc.identifier.doi10.4103/ijpm.ijpm_1236_21
dc.identifier.endpage510en_US
dc.identifier.issn0377-4929
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage502en_US
dc.identifier.urihttps:/dx.doi.org10.4103/ijpm.ijpm_1236_21
dc.identifier.urihttps://hdl.handle.net/20.500.12451/11025
dc.identifier.volume66en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofIndian Journal of Pathology and Microbiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectBladder Cancer
dc.subjectCD47
dc.subjectKİ-67
dc.subjectOCT-4
dc.subjectp53
dc.subjectSurvivin
dc.titleThe prognostic effect of immunohistochemical staining rates in patients with non-muscle-invasive bladder cancer
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu